How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com
TheraPb: Phase I/II Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma
Description:
This is a first-in-human, dose escalation and efficacy study of [212Pb]Pb-ADVC001 in participants with PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) who have not had prior exposure to [177Lu]Lu-PSMA based radioligand therapies.
Sponsor:
AdvanCellPhase:
Phase 1/2
Government Study Link:
NCT05720130 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Loading...
Share your feedback
Help us improve your experience